読み込み中
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
前日終値
$8.34
+$0.25 · +3.09%
市場前
$8.69
+$0.35 · +4.20%
10月12日 9:08 ET
日中の時刻はETです。市場データは遅延する場合があります。
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
日中レンジ
現在 $8.34
52週レンジ
現在 $8.34
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
91
大幅な割安
センチメント
63
強気
リスク
50
やや高いリスク
モメンタム
78
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
日中レンジ
現在 $8.34
52週レンジ
現在 $8.34
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 5373.7万 USD | — | −665.1万 USD | 665.1万 USD | — |
| 粗利益 | 5373.7万 USD | — | −665.1万 USD | 665.1万 USD | — |
| 研究開発 | 1915.6万 USD | 4814.3万 USD | 3172.9万 USD | 3581.4万 USD | 2992.9万 USD |
| 販売・一般管理 | 1767.9万 USD | 1795.9万 USD | 987.5万 USD | 1006.2万 USD | 676.4万 USD |
| 営業費用 | 3683.5万 USD | 6610.2万 USD | 4160.4万 USD | 4587.6万 USD | 3669.3万 USD |
| 受取利息 | 220万 USD | 390万 USD | — | — | — |
| 支払利息 | 110万 USD | 110万 USD | — | — | — |
| 減価償却費と償却費 | 39.1万 USD | 48.7万 USD | 49.9万 USD | 37万 USD | 954.4万 USD |
| 営業利益 | 1690.2万 USD | −6610.2万 USD | −4825.5万 USD | −3922.5万 USD | −3669.3万 USD |
| 純利益 | 2982.1万 USD | −4773.3万 USD | −5374.3万 USD | −4280.9万 USD | −3756.4万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$36.50
上昇余地（337.65%）この株式へのエクスポージャーを報告している上場投資信託です。
Avantis U.S. Small Cap Value ETFAVUV427.95万0.01%308.51億 USD0.25%$119.64-0.41%
First Trust Dow Jones Select MicroCap Index FundFDM74.34万0.28%2.61億 USD0.65%$88.39-0.74%
Dimensional - US Small Cap ETFDFAS33.09万0.00%338.69億 USD0.31%$78.35+0.32%
Dimensional - US Targeted Value ETFDFAT26.93万0.00%301.22億 USD0.33%$67.27-0.43%
iShares Micro-Cap ETFIWC24.47万0.02%13.17億 USD0.60%$183+0.11%
Avantis U.S. Small Cap Equity ETFAVSC23.01万0.01%30.82億 USD0.25%$69.98+0.03%
Avantis U.S. Equity ETFAVUS14.45万—148.63億 USD0.15%$130.52+0.35%
Hartford Multifactor Small Cap ETFROSC9.63万0.20%4747.96万 USD0.34%$54.20-0.15%Avantis U.S. Small Cap Value ETFAVUVFirst Trust Dow Jones Select MicroCap Index FundFDMDimensional - US Small Cap ETFDFASDimensional - US Targeted Value ETFDFATiShares Micro-Cap ETFIWCAvantis U.S. Small Cap Equity ETFAVSCAvantis U.S. Equity ETFAVUSHartford Multifactor Small Cap ETFROSCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
